LGD-4033 is a nonsteroidal selective androgen receptor modulator exclusively applied for preclinical laboratory research and relevant pharmacodynamic exploration, not licensed for clinical medication, human oral administration or food raw material production worldwide. It displays high selective binding affinity toward human androgen receptor, selectively activating anabolic pathways inside skeletal muscle and bone tissues while exerting minimal androgenic influence on prostate organ compared with traditional synthetic anabolic steroids. Major laboratory research directions include in-vivo animal modeling of sarcopenia and disease-induced muscle wasting, researchers utilize aging rodents and tumor-bearing animal models to investigate its efficacy on boosting lean muscle accretion, reducing muscle breakdown and alleviating cachexia triggered by malignant diseases or chronic consumptive illnesses. It is also commonly adopted in osteoporosis-related pharmacological trials to evaluate its capacity to raise bone mineral density and restrain abnormal bone resorption without inducing prostate hyperplasia side effects. Additionally, the compound serves as research tool in cell culture experiments to uncover androgen receptor mediated downstream protein synthesis signaling pathway and assist novel anti-atrophy drug structural optimization research. This substance is listed as prohibited doping agent by international anti-doping organizations, any illegal application for bodybuilding or sports performance improvement violates relevant pharmaceutical supervision laws in most countries.
GHS hazard is classified as Warning grade with H315 skin irritation and H319 serious eye irritation hazard statements, standardized personal protection is mandatory during all experimental manipulation. Laboratory personnel shall equip nitrile protective gloves, impact-resistant safety goggles and dustproof lab coat when weighing solid powder or preparing stock solution, refrain from inhaling fine dust, long-term skin contact and accidental swallowing of raw material. All leftover solid residues and waste organic solvent containing LGD-4033 must be sorted as hazardous chemical waste and delivered to authorized professional disposal agencies complying with local environmental legislation instead of daily domestic waste disposal. Existing preclinical animal toxicology data reveals continuous high-dose exposure can suppress endogenous testosterone synthesis, resulting in endocrine fluctuation, decreased libido and physical fatigue in tested subjects. Long-term high-concentration medication also carries potential mild hepatic metabolism burden and cardiovascular regulatory risks, while complete long-term carcinogenicity and reproductive toxicity evaluation data remains insufficient. Experiments involving pregnant laboratory animals shall exclude this test article for dosing due to unclear gestation-related toxic risks. Separate storage from strong oxidants and concentrated acidic chemicals to prevent unexpected chemical decomposition and purity degradation during long-term stock preservation.
